PMID: 9634197Jun 20, 1998Paper

The regulation of phenotype and function of human liver CD3+/CD56+ lymphocytes, and cells that also co-express CD8 by IL-2, IL-12 and anti-CD3 monoclonal antibody

Human Immunology
Y JinJ Miller

Abstract

The regulation of phenotype and function of human liver infiltrating lymphocytes (LIL) by in vitro culture with IL-2, IL-12 and anti-CD3 monoclonal antibodies (mAb) was investigated. The CD3+ LIL which express 50% less CD3 molecules per cell than peripheral blood T lymphocytes, exhibited a 6-fold reduction in proliferation when stimulated through the CD3 complex by anti-CD3 mAb. LIL freshly isolated or cultured in medium did not suppress MLR response, nor were they cytotoxic. However, treatment of the LIL cells with IL-2, IL-12 and anti-CD3 induced these cells to suppress autologous responding cells in MLR (ca. 70%) and to kill autologous or allogeneic cells. Low level cytotoxicity could be induced by cytokines IL-2, IL-12 or anti-CD3 alone. However, the development of optimum MLR suppression and cytotoxicity induction was dependent upon stimulation of the LIL cells through the CD3 complex. The co-expression of CD3 and CD56 on LIL was also up-regulated by anti-CD3 stimulation in the combination of IL-2 and IL-12. Most of the CD3+/CD56+ cells, also expressed CD8. After the magnetic bead separation procedure, the cytotoxic activity was found mainly in the CD3+/CD56+/CD8+ population. These results suggest that CD3+/CD56+/CD8+ cell...Continue Reading

References

Oct 1, 1992·Immunology Today·L L LanierJ H Phillips
Jul 1, 1986·The Journal of Experimental Medicine·R E SchmidtJ Ritz
Dec 3, 1987·The New England Journal of Medicine·M D Cooper
Sep 1, 1995·The Journal of Experimental Medicine·H R MacDonald
Apr 1, 1994·The Journal of Experimental Medicine·T Yoshimoto, W E Paul
Jul 1, 1994·The Journal of Experimental Medicine·M C Coles, D H Raulet
Jan 1, 1993·European Journal of Immunology·H AraseK Onoé
Jul 1, 1996·Immunology Today·B A Fields, R A Mariuzza
Feb 1, 1996·Immunology Today·A P Vicari, A Zlotnik
Oct 1, 1996·Immunology Today·M A Borrello, R P Phipps
Nov 1, 1996·Immunology Today·I N Crispe, W Z Mehal
May 19, 1997·The Journal of Experimental Medicine·S ValituttiA Lanzavecchia

❮ Previous
Next ❯

Citations

Sep 6, 2003·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Chichen Michael ChienShui-Tein Chen
Dec 17, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Li YeWenzhe Ho
Oct 16, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mark A Exley, Margaret James Koziel
Aug 24, 1999·European Journal of Immunology·S IshiharaT Juji
Nov 30, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Sarah M McAlpineJean S Marshall
May 18, 2012·Journal of Leukocyte Biology·Wei HouWen-Zhe Ho
Jul 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Emanuele Durante-MangoniMark A Exley
Feb 2, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mark A ExleyMargaret J Koziel
Feb 12, 2004·Cancer Research·Howard J WajchmanKenneth E Dombrowski
Aug 24, 1999·European Journal of Immunology·A A Delvig, J H Robinson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cell Adhesion Molecules in the Brain

Cell adhesion molecules found on cell surface help cells bind with other cells or the extracellular matrix to maintain structure and function. Here is the latest research on their role in the brain.